86215-57-8

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
Methyl 2-bromo-2-(3-methoxyphenyl)acetate is employed as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure allows it to serve as a versatile building block for the preparation of biologically active compounds, contributing to the development of new drugs and agricultural products.
Used in Flavor and Fragrance Industry:
Recognized for its fruity scent, Methyl 2-bromo-2-(3-methoxyphenyl)acetate is utilized as a flavor and fragrance ingredient. It plays a significant role in the production of perfumes and cosmetic products, enhancing their sensory appeal and providing a pleasant olfactory experience for consumers.
Used in Organic Synthesis:
As a reagent in organic synthesis, Methyl 2-bromo-2-(3-methoxyphenyl)acetate is instrumental in the creation of a wide range of chemical compounds. Its ability to participate in various chemical reactions makes it an indispensable tool for researchers and chemists working across different fields of chemistry.

Upstream product

• 54845-40-8 methyl 2-hydroxy-2-(3-methoxyphenyl)acetate 
• 591-31-1 3-methoxy-benzaldehyde 
• 18927-05-4 methyl (3-methoxyphenyl)acetate 
• 67-56-1 methanol 
• 7789-60-8 phosphorus tribromide 

Downstream Products

• 129592-95-6 methyl N-(trifluoroacetyl)-2-amino-2-(3-methoxyphenyl)acetate 
• 551929-17-0 (3-methoxy-phenyl)-[2-(4-methoxy-phenyl)-1,3-dioxo-indan-2-yl]-acetic acid methyl ester 
• 344245-50-7 cis-1-(m-methoxyphenyl)-1,2-cyclopropanedicarboxylic acid 
• 574729-23-0 (2-tert-butoxycarbonylamino-ethylamino)-(3-methoxy-phenyl)-acetic acid methyl ester 
• 551929-18-1 C₂₅H₂₂O₃ 
• 475631-86-8 (3-methoxy-phenyl)-[2-(4-methoxy-phenyl)-indan-2-yl]-acetic acid 
• 551929-19-2 C₂₅H₂₂O₂ 
• 1010445-74-5 tert-butyl 5-chloro-3-[methoxycarbonyl-(3-methoxyphenyl)methyl]-2-oxo-2,3-dihydrobenzimidazole-1-carboxylate 
• 66560-13-2 (1R,2S)-1-(3-Methoxy-phenyl)-cyclopropane-1,2-dicarboxylic acid dimethyl ester 

Relevant academic research and scientific papers

Compound with indoline skeleton, and preparation method and medical application of compound

The invention discloses a compound with an indoline skeleton, and a preparation method and medical application of the compound. The compound containing the indoline skeleton provided by the inventioncan interfere with Keap1-Nrf2 interaction activate Nrf2

Design, Synthesis, and Structure-Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors

The Keap1 (Kelch-like ECH-associated protein 1)-Nrf2 (nuclear factor erythroid 2-related factor 2)-ARE (antioxidant response element) pathway is the major defending mechanism against oxidative stresses, and directly disrupting the Keap1-Nrf2 protein-protein interaction (PPI) has been an attractive strategy to target oxidative stress-related diseases, including cardiovascular diseases. Here, we describe the design, synthesis, and structure-activity relationships (SARs) of indoline-based compounds as potent Keap1-Nrf2 PPI inhibitors. Comprehensive SAR analysis and thermodynamics-guided optimization identified 19a as the most potent inhibitor in this series, with an IC50 of 22 nM in a competitive fluorescence polarization assay. Further evaluation indicated the proper drug-like properties of 19a. Compound 19a dose-dependently upregulated genes and protein level of Nrf2 as well as its downstream markers and showed protective effects against lipopolysaccharide-induced injury in both H9c2 cardiac cells and mouse models. Collectively, we reported here a novel indoline-based Keap1-Nrf2 PPI inhibitor as a potential cardioprotective agent.

Diastereo- And Enantioselective Synthesis of Quaternary α-Amino Acid Precursors by Copper-Catalyzed Propargylation

A diastereo- and enantioselective propargylic substitution reaction between propargylic carbonates and α-substituted nitroacetates catalyzed by a Cu-pybox complex is described. This method allows the preparation of a series of non-proteinogenic quaternary α-amino acid precursors featuring two contiguous stereogenic centers and a terminal alkyne moiety in high yields with good to excellent diastereo- and enantioselectivities in most cases. The propargylated adducts were elaborated into a diverse set of quaternary α-amino acid derivatives.

1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, is described. Q can be pyridazin-3-yl, 6-fluoropyridazin-3-yl; R1 can be H; R2 and R3 can each independently be C1-C6 alkyl, or R2 and R3 taken together are —(CH2)3—; or R1 and R2 taken together can be —(CH2)2— and R3 can be —CH3; R4 halo, —CH3, —OCH3, —OCHF2, —OCF3, or —CN; and n can be 0, 1, or 2. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.

SUBSTITUTED PHENYLCARBAMATE COMPOUNDS

The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.

Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such

Compounds of formula (I): wherein X is O or S, R1 is acyl, aldehyde, cycloalkyl, an optionally substituted alkyl, alkenyl or alkynyl, R2 is H. alkyl, hydroxyalkyl, haloalkyl, alkenyl, or alkynyl; substituted alkyl; alkylcarbonyl; R3 and R4 are H, halogen, alkyl, alkenyl, alkynyl, alkoxyl, alkylthio, hydroxyalkyl, haloalkyl, haloalkenyl, or haloalkynyl; or R3 and R4 form an, optionally aromatic or heterocyclic, optionally substituted ring, R5 is H, halogen, trifluoromethyl, —CN, or —NO2; not all of R3, R4, and R5 being H, R6 and R9 are H, halogen, OH; alkyl. hydroxyalkyl, alkoxyl, thioalkyl, haloalkyl, alkenyl, or alkynyl; R7 and R8 are H, halogen, OH, SH; alkoxyl or alkylthio optionally substituted by OH and/or halogen; one of R7 and R8 not being H or halogen; or one of R7 and R8 is a pharmaceutically acceptable ester or thioester grouping, or R6 is C1-3-alkyl or, together with either R1 or R2, represents C1-3 alkylene or alkenylene linking group, optionally substituted by methyl, trifluoromethyl, OH, or halogen, and pharmaceutically acceptable salts and esters thereof, are useful as selective androgen modulators.

SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE

The present invention relates to novel benzimidazolone derivatives of the general formula (I) in which the substituents R1, R2, R3, A1, A2, and B are as defined in claim 1, medicaments comprising these, and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent diseases.

Substituted piperazines

Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

Indazole compounds useful as protein kinase inhibitors

The present invention provides compounds of formula I: or a pharmaceutically acceptable derivative thereof, wherein R1, R2, V1, V2, and V3 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of AKT, PKA, PDK1, p70S6K, or ROCK kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment of various disorders.

1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS

Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.